Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Open access

Abstract

Background and Aims: Normal alkaline phosphatase (ALP) levels in ursodeoxycholic acid (UDCA)-treated patients with primary biliary cholangitis (PBC) are associated with better long-term outcome. However, second-line therapies are currently recommended only when ALP levels remain above 1.5 times the upper limit of normal (×ULN) after 12-month UDCA. We assessed whether, in patients considered good responders to UDCA, normal ALP levels were associated with significant survival gains. Approach and Results: We performed a retrospective cohort study of 1047 patients with PBC who attained an adequate response to UDCA according to Paris-2 criteria. Time to liver-related complications, liver transplantation, or death was assessed using adjusted restricted mean survival time (RMST) analysis. The overall incidence rate of events was 17.0 (95% CI: 13.7–21.1) per 1000 out of 4763.2 patient-years. On the whole population, normal serum ALP values (but not normal gamma-glutamyl transpeptidase (GGT), alanine aminotransferase (ALT), or aspartate aminotransferase (AST); or total bilirubin < 0.6 ×ULN) were associated with a significant absolute complication-free survival gain at 10 years (mean 7.6 months, 95% CI: 2.7 - 12.6 mo.; p = 0.003). In subgroup analysis, this association was significant in patients with a liver stiffness measurement ≥ 10 kPa and/or age ≤ 62 years, with a 10-year absolute complication-free survival gain of 52.8 months (95% CI: 45.7–59.9, p < 0.001) when these 2 conditions were met. Conclusions: PBC patients with an adequate response to UDCA and persistent ALP elevation between 1.1 and 1.5 ×ULN, particularly those with advanced fibrosis and/or who are sufficiently young, remain at risk of poor outcome. Further therapeutic efforts should be considered for these patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/hep.0000000000000529

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 94

Metadata

Authors
Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., Eaton, J. E., Osman, K. T., Schramm, C., Sebode, M., Lohse, A. W., Dalekos, G., Gatselis, N., Nevens, F., Cazzagon, N., Zago, A., Russo, F. P., Floreani, A., Abbas, N., Trivedi, P., Thorburn, D., Saffioti, F., Barkai, L., Roccarina, D., Calvaruso, V., Fichera, A., Delamarre, A., Sobenko, N., Villamil, A. M., Medina-Morales, E., Bonder, A., Patwardhan, V., Rigamonti, C., Carbone, M., Invernizzi, P., Cristoferi, L., van der Meer, A., de Veer, R., Zigmond, E., Yehezkel, E., Kremer, A. E., Deibel, A., Bruns, T., Große, K., Wetten, A., Dyson, J. K., Jones, D., Dumortier, J., Pageaux, G.-P., de Lédinghen, V., Chazouillères, O., Carrat, F., & Groups, T. G. &. E. R.-L. P. S.
Affiliations
  • Inserm (FR)
  • University Health Network (CA)
  • Division of Gastroenterology and Liver Unit, University of Alberta, Edmonton, Alberta, Canada
  • University of Alberta (CA)
  • Liver Unit, Hospital Clínic, University of Barcelona, The August Pi i Sunyer Biomedical Research Institute, Biomedical Research Networking Center in Hepatic and Digestive Diseases, European Reference Network on Hepatological Diseases (ERN Rare-Liver), Barcelona, Spain
  • Universitat de Barcelona (ES)
  • Mayo Clinic (US)
  • University Medical Center Hamburg-Eppendorf (DE)
  • University Hospital of Larissa (GR)
  • KU Leuven (BE)
  • University of Padua (IT)
  • National Health Service (GB)
  • National Institute for Health and Care Research (GB)
  • The Royal Free Hospital (GB)
  • University College London Institute for Liver and Digestive Health, Royal Free Hospital, London, UK
  • Section of Gastroenterology and Hepatology, PROMISE, University of Palermo, Palermo, Italy
  • University of Palermo (IT)
  • Department of Hepatology, University Hospitals of Bordeaux, Pessac, France
  • Hospital Italiano de Buenos Aires (AR)
  • Department of Medicine, Division of Gastroenterology, Beth Israel Deaconess Medical Center, Boston, Massachusetts
  • Beth Israel Deaconess Medical Center (US)
  • Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT)
  • University of Milano-Bicocca (IT)
  • Department of Gastroenterology and Hepatology, Erasmus University Medical Center, Rotterdam, The Netherlands
  • Tel Aviv Sourasky Medical Center (IL)
  • University Hospital Zurich (CH)
  • Universitätsklinikum Aachen (DE)
  • Newcastle upon Tyne Hospitals NHS Foundation Trust (GB)
  • Hospices Civils de Lyon (FR)
  • Centre Hospitalier Universitaire de Montpellier (FR)
Corresponding author
Corpechot, Christophe
Venue
Hepatology
Published
2023-07-03
Volume
79
Issue
1
Pages
39-48
ISSN
0270-9139 (ISSN-L)
OpenAlex
W4383058381
Cited by
94
References
22
Citations by year
2026: 34 · 2025: 33 · 2024: 22 · 2023: 5
FWCI
15.73
Type
journal article
Language
en
Open access
Licence
cc-by
Locations
  • Hepatology (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • EUR Research Repository (Erasmus University Rotterdam) (publishedVersion, cc-by)
  • Lirias (submittedVersion, other-oa)
  • Padua Research Archive (University of Padova) (submittedVersion, other-oa)
  • BOA (University of Milano-Bicocca) (submittedVersion)
  • Nova Science Publishers (Nova Science Publishers, Inc.) (submittedVersion)
  • RWTH Publications (RWTH Aachen) (submittedVersion)
  • Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
  • Newcastle University ePrints (Newcastle Univesity)
Funders
  • Falk Foundation
  • Bristol-Myers Squibb
  • Eli Lilly and Company
  • GlaxoSmithKline
  • Gilead Sciences
  • CSL Behring
  • Kowa Company
  • National Institute for Health and Care Research (NIHR131359, NIHR200243, NF-SI-0513-10091)
  • Eisai
  • Swedish Orphan Biovitrum
  • Ipsen
  • AOP Orphan
  • Grifols
  • Dr. Falk Pharma
Topics
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
  • Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
  • Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
Keywords
primary biliary cirrhosis, ursodeoxycholic acid, alkaline phosphatase, treatment response, complication-free survival, liver complications, liver transplantation, liver stiffness measurement, liver fibrosis, prognosis
MeSH terms
Alkaline Phosphatase, Cholagogues and Choleretics, Humans, Liver Cirrhosis, Biliary, Middle Aged, Retrospective Studies, Ursodeoxycholic Acid, Treatment Outcome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? https://app.cochat.ai/papers/10.1097/hep.0000000000000529
The paper
Corpechot, C., Lemoinne, S., Soret, P.-A., Hansen, B., Hirschfield, G., Gulamhusein, A., Montano-Loza, A. J., Lytvyak, E., Pares, A., Olivas, I., Eaton, J. E., Osman, K. T., Schramm, C., Sebode, M., Lohse, A. W., Dalekos, G., Gatselis, N., Nevens, F., Cazzagon, N., . . . Groups, T. G. &. E. R.-L. P. S. (2024). Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain? Hepatology. https://doi.org/10.1097/hep.0000000000000529

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.